NVG-111

NVG-111 is a first-in-class, humanized, tandem single-chain variable fragment (scFv) bispecific antibody that targets both receptor tyrosine kinase-like orphan receptor 1 (ROR1) and CD3. One arm of the molecule binds to ROR1—a protein highly expressed on various hematologic malignancies and some solid tumors but largely absent from normal adult tissues—while the other arm binds to CD3 on cytotoxic T lymphocytes. This dual binding brings T cells into close proximity with cancer cells expressing ROR1, leading to MHC-independent immunological synapse formation and targeted tumor cell killing via perforin/granzyme B release and cytokine secretion. The drug is being developed primarily for relapsed/refractory chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), small lymphocytic lymphoma (SLL), follicular lymphoma (FL), diffuse large B cell lymphoma (DLBCL), as well as certain solid tumors such as non-small cell lung cancer (NSCLC) and malignant melanoma. Early clinical data show promising efficacy with a manageable safety profile[5][6][7][9].

Brand names

NVG-111NVG111NVG 111

Other names

anti-ROR1/CD3 T-cell engager NVG-111ROR1xCD3 bispecific T cell engagerROR-1xCD3 bispecific T cell engagerROR 1xCD3 bispecific T cell engagerROR1-targeting bispecific antibody T-cell engagerROR-1-targeting bispecific antibody T-cell engagerROR 1-targeting bispecific antibody T-cell engager